REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, today announced it entered into a license agreement with Pfizer Inc.
{iframe}https://finance.yahoo.com/news/regenxbio-announces-license-agreement-pfizer-110700748.html?mc_cid=edfb0444be&mc_eid=8540dbbde5{/iframe}